Aug. 1 at 11:31 PM
$SIBN Heads up alert! Only three days until Upcoming earnings on Monday, 8/4/2025 for
$SIBN
Neutral (5.3)
### SI-BONE, Inc.
Financial Analysis
SI-BONE, Inc.
(NASDAQ: SIBN) has demonstrated a commendable performance with its shareholders enjoying an 8.6% compound annual growth rate (CAGR) over the last three years, indicating a stable upward trajectory in shareholder value.
As a medical device company focusing on sacropelvic disorders, SI-BONE is strategically positioned in a niche market with promising growth prospects.
The company's P/E ratio remains competitive within the industry, suggesting that its current stock price is reasonably aligned with its earnings.
This reflects market confidence in its business model and future earnings potential.
The EPS growth has shown positive momentum, which is a critical indicator of the company's profitability and operational efficiency.
Furthermore, SI-BONE's revenue forecasts suggest a robust upward trend, driven by increased adoption of its innovative solutions and expansion into new markets.
When compared to industry peers, SI-BONE maintains a strong position, leveraging its specialized focus and innovative product offerings to capture market share and enhance revenue streams.
### Upcoming Earnings Report
SI-BONE is set to release its second-quarter financial results on August 4, 2025.
Historically, the company has consistently met or exceeded analyst expectations, which has contributed to its favorable market perception.
Analyst consensus estimates for the upcoming earnings report indicate a positive outlook, with expectations of continued revenue growth and sustained profitability.
The anticipated financial performance is likely to have a significant impact on the stock, as investors will be keen to assess the company's ability to maintain its growth trajectory and capitalize on emerging opportunities in the sacropelvic disorder treatment market.
### Sector Performance
SI-BONE operates within the medical device sector, which has exhibited robust performance in recent times.
The sector is characterized by ongoing innovation, regulatory developments, and a strong demand for advanced medical solutions.
Despite macroeconomic challenges, the sector has shown resilience, supported by an aging population and increasing healthcare expenditures.
SI-BONE, with its focused niche and innovative approach, is well-positioned to benefit from the sector's growth dynamics, enhancing its potential to deliver long-term value to shareholders.
- Funds were net buyers of
$SIBN during the previous reporting quarter.
- Funds with large holdings in
$SIBN include:
- OrbiMed Advisors LLC, MV:
$48MM. Fund Rank: 55%
www.orbimed.com
- First Light Asset Management LLC, MV:
$23MM. Fund Rank: 55%
www.firstlightam.com
- Granahan Investment Management Inc, MV:
$20MM. Fund Rank: 70%
www.granahan.com
- Holocene Advisors LP, MV:
$8MM. Fund Rank: 92%
www.holoceneadvisors.com
- Pier Capital LLC, MV:
$7MM. Fund Rank: 63%
www.piercap.com
- Last 10 days performance: -1%
- Last 30 days performance: -8%
- Last 90 days performance: 22%
Some of the latest news articles:
- Title: SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
Publication Date: 7/29/2025 8:30:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/si-bone-present-canaccord-genuity-203000440.html?.tsrc=rss
- Title: SI-BONE (NASDAQ:SIBN) shareholders have earned a 8.6% CAGR over the last three years
Publication Date: 7/29/2025 1:42:16 PM, Source: yahoo
URL: https://finance.yahoo.com/news/si-bone-nasdaq-sibn-shareholders-134216181.html?.tsrc=rss
- Title: SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
Publication Date: 7/14/2025 8:09:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/si-bone-report-second-quarter-200900479.html?.tsrc=rss
Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
